文献速递呼吸衰竭与机械通气儿科与产科急症

高流量鼻导管与鼻持续气道正压用于小婴儿急性病毒性细支气管炎初始呼吸管理的多中心随机对照试验(TRAMONTANE研究)

High flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory management of acute viral bronchiolitis in young infants: a multicenter randomized controlled trial (TRAMONTANE study).
PubMed 文献 · Intensive Care Med · 2017-01-26
一句话结论在≤6月龄中重度急性病毒性细支气管炎婴儿中,HFNC初始呼吸支持24小时失败率未达到非劣于nCPAP,nCPAP成功相对风险为1.63。

TRAMONTANE研究为五家儿科ICU开展的多中心随机对照试验,纳入142例≤6月龄中重度急性病毒性细支气管炎婴儿,比较7 cmH2O nCPAP与2 L/kg/min HFNC氧疗的初始呼吸管理。主要终点为随机后24小时内预设标准的失败率,HFNC失败率需在nCPAP失败率15%以内才满足非劣效;风险差-19%(95%CI -35至-3%)未达非劣效(p=0.707)。优效性分析提示nCPAP成功相对风险为1.63(95%CI 1.02-2.63)。两组交叉后替代呼吸支持成功率、插管率、无创和有创通气时长、皮肤损伤及PICU住院时长相当,无气漏综合征或死亡。

要点

  • ≤6月龄中重度AVB婴儿中,HFNC初始呼吸支持24小时失败率未达到非劣于nCPAP(风险差-19%,95%CI -35至-3%,p=0.707)。
  • 优效性分析提示nCPAP成功相对风险为1.63(95%CI 1.02-2.63),高于HFNC。
  • 两组交叉后替代呼吸支持成功率、插管率、无创和有创通气时长、皮肤损伤及PICU住院时长相当。
  • 研究中无患者发生气漏综合征或死亡。
  • 该试验在五家儿科ICU开展,纳入142例婴儿,两组均等分布。

适用人群与场景

  • ≤6月龄中重度急性病毒性细支气管炎婴儿,在儿科ICU接受初始呼吸支持。

诊断标准与关键阈值

  • 主要终点失败判定采用预设标准,评估随机后24小时内是否失败。
  • 非劣效界值:HFNC失败率需在nCPAP失败率15%以内。

处置流程与药物剂量

  • nCPAP组:7 cmH2O鼻持续气道正压。
  • HFNC组:2 L/kg/min氧疗经高流量鼻导管给药。

研究设计与关键结果

  • 多中心随机对照试验,五家儿科ICU,2014年11月至2015年3月纳入142例≤6月龄中重度AVB婴儿,两组均等分布。
  • 主要终点:随机后24小时失败率风险差-19%(95%CI -35至-3%),未达HFNC非劣效(p=0.707)。
  • 优效性分析:nCPAP成功相对风险1.63(95%CI 1.02-2.63),高于HFNC。
  • 次要终点:交叉后替代呼吸支持成功率、插管率、无创和有创通气时长、皮肤损伤及PICU住院时长两组相当。
  • 无患者发生气漏综合征或死亡。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(TRAMONTANE研究),注册号NCT 02457013。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在≤6月龄中重度AVB婴儿中,以HFNC作为初始呼吸支持未显示与nCPAP相似的24小时失败率。
  • 优效性分析提示nCPAP在初始呼吸支持成功方面可能优于HFNC(相对风险1.63,95%CI 1.02-2.63)。
  • 两组在交叉后替代呼吸支持、插管率、通气时长、皮肤损伤及PICU住院时长方面相当,无气漏综合征或死亡。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Nasal continuous positive airway pressure (nCPAP) is currently the gold standard for respiratory support for moderate to severe acute viral bronchiolitis (AVB). Although oxygen delivery via high flow nasal cannula (HFNC) is increasingly used, evidence of its efficacy and safety is lacking in infants.

METHODS: A randomized controlled trial was performed in five pediatric intensive care units (PICUs) to compare 7 cmH2O nCPAP with 2 L/kg/min oxygen therapy administered with HFNC in infants up to 6 months old with moderate to severe AVB. The primary endpoint was the percentage of failure within 24 h of randomization using prespecified criteria. To satisfy noninferiority, the failure rate of HFNC had to lie within 15% of the failure rate of nCPAP. Secondary outcomes included success rate after crossover, intubation rate, length of stay, and serious adverse events.

RESULTS: From November 2014 to March 2015, 142 infants were included and equally distributed into groups. The risk difference of -19% (95% CI -35 to -3%) did not allow the conclusion of HFNC noninferiority (p = 0.707). Superiority analysis suggested a relative risk of success 1.63 (95% CI 1.02-2.63) higher with nCPAP. The success rate with the alternative respiratory support, intubation rate, durations of noninvasive and invasive ventilation, skin lesions, and length of PICU stay were comparable between groups. No patient had air leak syndrome or died.

CONCLUSION: In young infants with moderate to severe AVB, initial management with HFNC did not have a failure rate similar to that of nCPAP. This clinical trial was recorded in the National Library of Medicine registry (NCT 02457013).

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Milési C, Essouri S, Pouyau R, et al. High flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory management of acute viral bronchiolitis in young infants: a multicenter randomized controlled trial (TRAMONTANE study). Intensive Care Med. 2017. PMID: 28124736. doi:10.1007/s00134-016-4617-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。